Physician profile
Risa Barton
NPI 1639379092
$3,125.56
in general payments reported to CMS, 2019-2025
37 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $417 · 2023: $404 · 2024: $702 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,416 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.14 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $538.29 | 2023-2025 | Tecvayli, Darzalex, Erleada |
| Incyte Corporation | $359.35 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $284.02 | 2022-2025 | Lynparza, Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $155.74 | 2021-2024 | Opdivo |
| Astellas Pharma US INC | $155.12 | 2023-2025 | Vyloy, Padcev, Xtandi |
| Genentech USA, INC. | $154.07 | 2021-2025 | Tecentriq, Venclexta, Itovebi |
| Merck Sharp & Dohme LLC | $150.38 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $97.92 | 2022-2025 | |
| Eisai INC. | $93.99 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $93.67 | 2023-2024 | Libtayo |
| Glaxosmithkline, LLC. | $93.66 | 2024-2025 | Ojjaara, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $86.14 | 2024-2025 | Fruzaqla, Ninlaro |
| Celgene Corporation | $82.05 | 2022-2025 | Reblozyl |
| Pfizer INC. | $79.48 | 2021-2025 | |
| Taiho Oncology, INC. | $68.24 | 2022-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $66.88 | 2022-2024 | Brukinsa |
| Abbvie INC. | $59.52 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $57.04 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $50.75 | 2024-2025 | Orgovyx |
| Genzyme Corporation | $45.43 | 2021-2023 | |
| Array Biopharma INC | $39.90 | 2023-2024 | Braftovi, Mektovi, Tukysa |
| Emd Serono, INC. | $34.87 | 2022-2023 | Bavencio |
| Aveo Pharmaceuticals, INC. | $33.28 | 2024-2025 | |
| Gilead Sciences, INC. | $21.27 | 2025 | Trodelvy |
| Caris Mpi, INC. | $21.00 | 2025 | Mi Cancer Seek |
| Exelixis INC. | $20.80 | 2024 | Cabometyx |
| Heron Therapeutics, INC. | $18.99 | 2022 | |
| Mirati Therapeutics, INC. | $17.91 | 2023 | Krazati |
| Deciphera Pharmaceuticals INC. | $17.69 | 2024 | Tgct, Qinlock |
| Tersera Therapeutics LLC | $17.67 | 2025 | Zoladex |
| Cti Biopharma Corp. | $17.32 | 2023 | Vonjo |
| Sobi, INC | $16.91 | 2025 | |
| Adc Therapeutics America, INC. | $16.66 | 2025 | |
| Amgen INC. | $15.74 | 2023 | Lumakras |
| Alexion Pharmaceuticals, INC. | $15.01 | 2025 | Ultomiris |
| Beone Medicines USA, INC. | $15.00 | 2025 | Tevimbra |
| G1 Therapeutics, INC. | $13.80 | 2023 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Risa Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.